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Lactobacillus helveticus is an important industrial thermophilic starter that is predominantly
employed in the fermentation of milk for the manufacture of several cheeses. In addition
to its technological importance, a growing body of scientific evidence shows that strains
belonging to the L. helveticus species have health-promoting properties. In this review, we
synthesize the results of numerous primary literature papers concerning the ability of L.
helveticus strains to positively influence human health. Several in vitro studies showed that
L. helveticus possesses many common probiotic properties, such as the ability to survive
gastrointestinal transit, adhere to epithelial cells, and antagonize pathogens. In vivo stud-
ies in murine models showed that L. helveticus could prevent gastrointestinal infections,
enhance protection against pathogens, modulate host immune responses, and affect the
composition of the intestinal microbiota. Interventional studies and clinical trials have also
demonstrated a number of health-promoting properties of L. helveticus. Finally, several
studies suggested that specific enzymatic activities of L. helveticus could indirectly ben-
efit the human host by enhancing the bioavailability of nutrients, removing allergens and
other undesired molecules from food, and producing bioactive peptides through the diges-
tion of food proteins. In conclusion, this review demonstrates that in light of the scientific
literature presented, L. helveticus can be included among the bacterial species that are
generally considered to be probiotic.
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INTRODUCTION
Lactobacilli are strictly fermentative bacteria of the phylum Fir-
micutes that live in a variety of environmental niches, wherever
high levels of nutrients (particularly sugars and organic nitrogen)
are present (Hammes et al., 1992). Comparative genome analy-
ses demonstrated that during its evolution, the genus Lactobacillus
diverged from its ancestors through an extensive loss of genes,
which was likely triggered by the transition to nutritionally rich
environments (Makarova et al., 2006). Currently, the genus Lacto-
bacillus comprises more than 80 different species, most of which
can be clustered according to their phylogenetic relationships into
seven groups: the Lactobacillus buchneri group, the Lactobacillus
casei group, the Lactobacillus delbrueckii group, the L. plantarum
group, the L. reuteri group, the L. sakei group, and the L. salivarius
group (Hammes et al., 1992).
The L. delbrueckii group comprises scientifically well-known
homofermentative bacteria that are typically isolated from human
and animal intestinal tracts (L. acidophilus, L. crispatus, L. gasseri,
L. johnsonii) or from fermented foods (L. delbrueckii, L. helveticus).
Within the L. delbrueckii group, the species L. acidophilus and L.
helveticus are phylogenetically very closely related (the 16S rDNA
sequences of these bacteria differ by just 1.6%; Callanan et al.,
2008); however, while L. helveticus is a specialist dairy culture, L.
acidophilus is a natural inhabitant of the human gut. Further-
more, L. acidophilus strains are commonly used as probiotics,
defined by the Food and Agriculture Organization of the United
Nations (FAO) as “live microorganisms which when administered
in adequate amounts confer a health benefit on the host ” (Food
and Agriculture Organization/World Health Organization, 2002).
More than 250 scientific studies have been published concerning
the probiotic potential of L. acidophilus in less than 3 years (from
January 2010 to August 2012, according to a PubMed search),
whereas L. helveticus has been included in less than 20 studies on
probiotics in the same period. Although limited, the literature on
the potential beneficial effects of L. helveticus includes significant
scientific facts that highlight the ability of L. helveticus strains to
interact with the host and influence health.
Here, we review the scientific literature in which L. helveticus
cells and cell components, or the enzymatic activities of this bac-
terium, have been linked to specific effects on host physiology.
The purpose of this review is to provide scientific evidence that
the species L. helveticus includes strains that can be properly con-
sidered to be probiotic. To this aim, we examined more than 50
scientific publications on the probiotic properties of L. helveti-
cus, including in vitro characterizations, in vivo animal studies,
and interventional/clinical trials. The publications cited in this
review demonstrate that members of the species L. helveticus can
potentially affect human health through direct or indirect mech-
anisms, such as the inhibition of pathogens, modification of gut
microbiota, modulation of the host immune system, generation of
bioactive peptides from food molecules, or improvement of food
quality.
INHIBITION OF FUNGAL AND BACTERIAL PATHOGENS: THE
ROLE OF L. hELVETICUS IN THE PREVENTION AND
TREATMENT OF INFECTIONS
Infectious diseases represent a perpetual threat to human health.
According to the 2004 World Health Report from the World
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Health Organization (WHO) (2004), infectious diseases are the
second-leading cause of death following cardiovascular diseases,
responsible for about 26% of the deaths that occurred worldwide
in 2002. The acquisition of antimicrobial resistance by pathogens,
and the subsequent spreading of resistant microorganisms, is a
major health concern. Resistance is mainly caused by the mis-
use of antibiotics that often are prescribed unnecessarily (Wise
et al., 1998). In this context, the use of probiotic microorganisms
able to exert an antagonistic activity toward pathogens can rep-
resent an alternative intervention to prevent infections and might
reduce excessive administration of antibiotics. Several studies have
demonstrated that L. helveticus is effective in preventing infections.
In a study performed by Vinderola et al. (2007a), strain L. hel-
veticus R389, which does not adhere to the intestinal epithelium,
exerted a protective action against Salmonella enteritidis serovar
Typhimurium infection in mice. L. helveticus was also demon-
strated to antagonize Campylobacter jejuni in vitro, which is the
leading cause of enterocolitis in humans in several countries (Tern-
hag et al., 2008). L. helveticus strain R0052 efficiently reduced the
invasion of two different strains of C. jejuni in human colon can-
cer epithelial T84 cells (Wine et al., 2009). Heat-inactivated L.
helveticus cells were observed to maintain part of the antagonis-
tic activity, suggesting that the capacity of L. helveticus to block
pathogen invasion is not completely dependent on the presence of
metabolically active bacterial cells, and that this capacity could be
due to the presence of specific cell components, such as the S-layer
protein, on the bacterial surface (Johnson-Henry et al., 2007; Wine
et al., 2009).
Lactobacillus helveticus was also demonstrated to act synergis-
tically with other bacterial strains to antagonize pathogens. For
example, L. helveticus strain R0052 was used in combination with
L. rhamnosus to treat mice infected with Citrobacter rodentium,
a murine pathogen that mimics the infections caused in humans
by enterohemorrhagic E. coli (EHEC). Specifically, when C57BL/6
mice were pretreated with a mixture of the two lactobacilli and
then infected with C. rodentium, the authors observed a reduc-
tion in weight loss, colonic epithelial cell hyperplasia, and mucosal
barrier dysfunctions, thus resulting in an increased survival of the
neonatal mice (Gareau et al., 2010).
The ability of a bacterium and/or its components to specifi-
cally inhibit a harmful microorganism might also result in a wider
beneficial protective action. Pathogens often compromise host cell
defense mechanisms and immune responses to infections caused
by other etiological agents (Bhavsar et al., 2007). For instance,
EHEC inhibits interferon (IFN)-γ-stimulated tyrosine phospho-
rylation of signal transducer and activator of transcription-1
(STAT-1) in different cell lines (Ceponis et al., 2003), which is
an essential signaling pathway in mounting an innate immune
response against several bacterial infections (Shtrichman and
Samuel, 2001). In research carried out by Jandu et al. (2009), L.
helveticus R0052 was demonstrated to counteract E. coli O157:H7-
induced inhibition of STAT-1 tyrosine phosphorylation on three
different epithelial cell lines (407, Caco-2, and HEp cells), whereas
L. rhamnosus R0011 failed to protect cells against pathogen-
induced alterations of innate immunity. Moreover, it was demon-
strated that intact viable cells were essential to counteract pathogen
activity, since boiled cells, conditioned medium, and culture
supernatant did not exert any antagonism.
Single molecules isolated from bacterial cells have been demon-
strated to be effective against pathogens. For instance, the S-layer
protein purified from L. helveticus strain R0052 was able to inter-
fere with the adhesion of E. coli O157:H7 onto human epithelial
HEp-2 cells (derived from larynx epidermoid carcinoma tissue)
and to attenuate the pathogen-induced drop in trans-epithelial
resistance in human colon carcinoma-derived T84 cells, therefore
preserving barrier integrity and functions (Johnson-Henry et al.,
2007). A subsequent study demonstrated that the S-layer pro-
tein of L. helveticus strain M92 mediates the auto-aggregation of
the bacterium and co-aggregation with Salmonella Typhimurium
FP1, contributing to the competitive exclusion of the pathogen
(Beganovic et al., 2011).
Interestingly, L. helveticus can display efficient epithelium adhe-
sion and pathogen inhibition in body sites other than the gut. In
fact, L. helveticus strain MIMLh5, isolated from Grana Padano
natural whey starter, adhered efficiently to both the human
hypopharyngeal epithelial cell line FaDu and HaCat keratinocytes,
and inhibited the adhesion of Streptococcus pyogenes (the etio-
logical agent of numerous diseases, including sore throat and
acute rheumatic fever) better than the 10 probiotic and dairy
lactic acid bacterial strains tested (Guglielmetti et al., 2010b).
It was also demonstrated that L. helveticus interfered with the
adhesion of pathogens onto uro-vaginal surfaces. For instance,
L. helveticus KS300, a hydrogen peroxide-producing strain iso-
lated from the human vagina, inhibited the growth and reduced
the viability of vaginosis-associated bacteria Gardnerella vagi-
nalis and Prevotella bivia, uropathogenic E. coli and diarrheagenic
Salmonella Typhimurium (Atassi et al., 2006). Moreover, strain
KS300 interfered with cell adhesion and the entry of uropath-
ogenic Dr adhesin-positive E. coli (Nowicki et al., 1987) and
diarrheagenic S. Typhimurium in human cervical HeLa and Caco-
2/TC7 enterocyte-like cell lines, as well as G. vaginalis adhesion
onto HeLa cells (Atassi et al., 2006). Furthermore, it was recently
shown that L. helveticus HY7801 inhibited Candida albicans-
induced vaginitis in mice more potently than three other lactic
acid bacteria (LAB) strains, including L. delbrueckii ssp. Bulgari-
cus HY7901, L. gasseri HY7022, and L. fermentum CS332 (Joo et al.,
2012). The use of strain HY7801, both orally and intra-vaginally,
decreased myeloperoxidase activity in vaginal tissue, which is nor-
mally caused by C. albicans proliferation (Joo et al., 2012). It was
also demonstrated that L. helveticus exerted its protective effect
when administered orally. Consequently, it has been suggested that
L. helveticus may act not only through the production of hydro-
gen peroxide, lactic acid, or other antimicrobial products, but also
by stimulating host immunity at the systemic level. The benefi-
cial effects exerted by L. helveticus in the vagina are of particular
relevance to recurrent vulvo-vaginal candidiasis, which is at least
partially caused by the spread of resistant C. albicans strains that
can originate from prolonged antimicrobial treatments (Rogers,
2002).
In conclusion, strains of L. helveticus have the ability to inhibit
different pathogenic microorganisms. Considering its GRAS/QPS
status, the consumption of L. helveticus cells represents an effective
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and safe strategy for the prevention of pathogen colonization and
proliferation.
THE IMPACT OF L. hELVETICUS ON HOST MICROBIOTA
COMPOSITION AND THE METABOLIC PROFILE
Strains belonging to the L. helveticus species can exert beneficial
effects on the host’s health by positively affecting the micro-
biota composition of a specific body site. In an in vivo study
using fecal plate counts in mice, the administration of L. hel-
veticus M92 for 8 days increased the levels of total LAB and
decreased total enterobacteria and sulfur-reducing clostridia; this
effect was particularly evident when strain M92 was used in com-
bination with different prebiotic fibers (especially inulin) in a
symbiotic preparation (Frece et al., 2009). The authors stated that
the effect exerted by L. helveticus on the composition of the gut
microbiota might depend on the production of lactic acid and
bacteriocins. The same M92 strain was also orally administered
for 7 days to Swiss albino mice in combination with Salmonella
Typhimurium FP1. The administration of L. helveticus caused a
decrease of both total enterobacterial and Salmonella spp. counts
by approximately 2 log units, compared to mice infected only
with the pathogen (Beganovic et al., 2011). In another study, L.
helveticus 416 was used in association with Enterococcus faecium
CRL 183 in an aqueous soy extract (Cavallini et al., 2011). After
60 days of treatment in rabbits, the administration of the pro-
biotic soy product caused a reduction of the Enterobacteriaceae
population (represented mainly by Escherichia coli, Salmonella
spp., Shigella spp., Yersinia enterocolitica, Klebsiella spp., Proteus
spp., and Citrobacter spp.) and a significant increase in Entero-
coccus spp., Lactobacillus spp. and Bifidobacterium spp., which are
known to be beneficial to the host’s health (Mitsuoka, 1990). This
effect was due to the presence and activity of L. helveticus and
E. faecium, since the unfermented product did not induce any
modification of the gut microbiota. Interestingly, the modification
of the microbiota composition was accompanied by an improve-
ment in the lipid profile of the host, measured as a reduction
of total cholesterol, non-HDL cholesterol, and auto-antibodies
against oxidized LDL; at the same time, HDL cholesterol was
increased. In addition, rabbits fed with the probiotic prepara-
tion presented a lower extent of atherosclerotic lesion areas in
aortic segments. Cavallini et al. (2011) hypothesized that hypoc-
holesterolemic effects induced by bacteria such as Lactobacillaceae
and bifidobacteria can occur through various mechanisms, includ-
ing the deconjugation of bile salts (which cannot be absorbed in
the deconjugated form and must be produced again in the liver
starting from cholesterol) and the production of propionate and
butyrate (which inhibit fatty acid and cholesterol synthesis in
the liver; Trautwein et al., 1998). Another study concerning the
regulation of lipid metabolism and inflammatory processes was
carried out by testing the ability of different LAB to reduce the
production of leukotriene B4 (LTB4; Kimoto-Nira et al., 2009),
which is a bioactive lipid generated from arachidonic acid by 5-
lipoxygenase and associated with inflammation, allergic reactions,
and carcinogenesis when present in excessive amounts. Among a
series of LAB tested, L. helveticus Bc-10 demonstrated the highest
inhibitory capacity on the Ca2+ ionophore-induced production
of LTB4 in the murine macrophage cell line J774.1. Interestingly,
heat-inactivated bacterial cells and intracellular cell-free extract
maintained the capacity to reduce LTB4 expression (Kimoto-Nira
et al., 2009).
The administration of L. helveticus also affects the metabolic
profile of fecal samples. Vitali et al. (2012) analyzed volatile com-
pounds in feces through solid-phase microextraction followed
by gas chromatography and mass spectrometry. The results of
this study indicated that the administration of L. helveticus strain
Bar13 to healthy human subjects resulted in a significant increase
in butyrate. The production of short-chain fatty acids such as
butyrate represented a benefit for gut homeostasis and was likely
due to the high secretion of lactate and the consequent conver-
sion of lactate to butyrate by lactate-utilizing bacteria (Duncan
et al., 2004). Butyrate is recognized as a specific growth stimulator
for colonic epithelial cells and is involved in the reinforcement of
barrier integrity, the amelioration of mucosal inflammation, and
the oxidative status of the host (Canani et al., 2011). Moreover,
butyrate provides protection against colorectal cancer by induc-
ing apoptosis specifically in tumor cells (Hague et al., 1993). In
the same study (Vitali et al., 2012), batch culture fermentations
of fecal samples by L. helveticus Bar13 reduced the fecal concen-
tration of pyridine. Heterocyclic aromatic amines (HCAs) such
as pyridine, which are derived from cooking meat and fish, are
involved in the etiology of colon cancer in humans (Felton et al.,
1997). Several studies reported the ability of LAB to bind HCAs
on their bacterial cell wall (Bolognani et al., 1997), preventing the
mucosal absorption of these compounds. L. helveticus may exert
the detoxifying activity observed by Vitali et al. (2012) through an
analogous mechanism.
The administration of L. helveticus also affects the microbiota
composition of the human vaginal mucosa. Treatment with L.
helveticus KS300 modified the vaginal microbiota by eliciting an
increase in Lactobacillaceae and Moraxellaceae and decreasing
Pastereullaceae, thus counteracting the effects of C. albicans on
these microbial populations (Atassi et al., 2006).
L. hELVETICUS MODULATES HOST IMMUNE RESPONSES
Increasing evidence supports the idea that one of the major mech-
anisms through which beneficial microbes can positively affect
the host’s health involves their ability to interact with the host’s
immune system by eliciting responses at both the local level and
the systemic level (Borchers et al., 2009; Lebeer et al., 2010; Tav-
erniti and Guglielmetti, 2011). Several studies reported the ability
of strains belonging to the L. helveticus species to exert immunos-
timulatory effects, both when used alone or in combination with
other bacterial strains. For instance, L. helveticus strain R0052 was
used in association with Bifidobacterium longum and Streptococ-
cus thermophilus to ferment both a soy beverage and a milk-based
blend. When these mixtures were added to the intestinal epithelial
cell lines HT29 and T84 before stimulation with tumor necro-
sis factor (TNF)-α, they significantly decreased the expression of
the chemokine interleukin (IL)-8 (Wagar et al., 2009). Further-
more, Ng and Griffiths (2002) observed that cultured macrophages
conditioned with L. helveticus-fermented milk (LhFM) or its
cell-free supernatant were stimulated to secrete IL-6, whereas
Laffineur et al. (1996) demonstrated that the cell-free supernatant
of L. helveticus-fermented β-casein-enriched medium was able to
modulate the proliferation of lymphocytes in vitro. In another
study, mice received milk fermented with L. helveticus R389 or
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the correspondent non-bacterial fraction (NBF; i.e., fermented
milk devoid of bacterial cells) before being infected with Sal-
monella Typhimurium. Both treatments caused an increase in
immunoglobulin (Ig)-A producing cells in the lamina propria of
the small intestine and a higher luminal content of both total S-
IgA and specific anti-Salmonella IgA (Vinderola et al., 2007b,c).
Previously, Leblanc et al. (2004) isolated the peptidic fraction
of milk fermented by L. helveticus R389 using size-exclusion-
HPLC and fed mice the extracts before infecting them with E.
coli O157:H7. The authors observed an increase in IgA produc-
ing B-lymphocytes, total intestinal IgA secretion, and total serum
IgA, indicating a stimulation of the systemic immune response.
Similarly, Frece et al. (2009) reported that the administration of L.
helveticus M92, both alone in milk and in a symbiotic preparation,
augmented the levels of fecal secretory IgA in mice and total serum
IgA. These data suggest that the stimulation of mucosal immunity
could play a pivotal role in the protection against pathogens. The
administration of milk fermented by L. helveticus strains repre-
sents a potential alternative treatment for the prevention of enteric
infections, which is likely mediated by the production of bioactive
compounds. Peptides derived from the high proteolytic activity of
L. helveticus on food proteins have been demonstrated to stimulate
the host’s immune system. A study by Leblanc et al. (2004) showed
that the peptides derived from the proteolytic activity of L. helveti-
cus R389 on milk induced in a BALB/c murine modela T helper
(Th) 2 response, which is an adaptive immune reaction based on
humoral responses mounted by a specialized sub-population of T
helper lymphocytes. This effect was evidenced by the increased
level of serum IL-4, and a concomitant reduction of the pro-
inflammatory cell-mediated Th1 response. In another study, three
distinct fractions of milk fermented by L. helveticus R389, contain-
ing different size of peptides (Fraction I, II, and III respectively for
large, medium, and small size), were fed to mice that were subse-
quently treated with methylcholanthrene crystals to induce tumor
formation. All fractions tested caused an increase in IgA+B cells
in gut-associated lymphoid tissue (GALT), with Fractions II and
Fraction III showing a stronger effect, likely due to the presence
of a high percentage of l-tryptophan (LeBlanc et al., 2002). Diets
supplemented with the peptide fractions also ameliorated tumor
progression, as revealed by a reduction in the induced fibrosar-
coma volume. The authors suggested that the observed effect could
be mediated by the induction of cytokine production from cells
involved in inflammatory responses (Perdigón et al., 1999).
Since the GALT is connected to other mucosal-associated lym-
phoid tissues (MALT), the activation of B and T cells can induce
their migration to other sites depending on the type of stimu-
lus, resulting in a systemic modulation of the immune response.
Accordingly, Matar et al. (2001) found an induction of IgA-
secreting cells both in the small intestine and in the bronchus
of mice fed milk fermented by L. helveticus R389. In mice, the
oral administration of milk fermented by a wild-type strain and
a non-proteolytic variant stimulated the immune system and
had antitumoral effects, as demonstrated by the regression of a
subcutaneously implanted fibrosarcoma. Interestingly, the admin-
istration of milk fermented by both strains caused activation of
the phagocytic activity of peritoneal macrophages, whereas the
increase of IgA-secreting cells in the gut and bronchus was not
significant when the non-proteolytic variant was used. In another
study in mice, a delay in breast cancer growth was observed after
the administration of either L. helveticus R389 or kefir fermented
by the same strain (de Moreno de LeBlanc et al., 2006). The results
demonstrated that both the probiotic strain alone and the fer-
mented product were able to positively affect murine health, even
in mucosal sites distant from the direct site of action, resulting in
a systemic immune activation.
In a similar study, a 7-days administration of two milk prepa-
rations fermented by strains L. helveticus 389 and L89 resulted in
breast tumor regression in mice. In particular, the administration
of milk fermented with strain 389 increased IL-10 and decreased
of IL-6 levels, both in the serum and in the mammary glands.
Based on these results, the authors suggested that L. helveticus 389
may have an effect in the link between immune and endocrine
responses (de Moreno de LeBlanc et al., 2005).
In another study, the NBF of milk fermented with L. helveticus
R389 was fed to BALB/c mice (Vinderola et al., 2007a). In mice that
received a diet supplemented with the NBF preparation, a non-
specific stimulation of the immune system occurred (MacPherson
et al., 2000; Fagarasan et al., 2001), as demonstrated by an increase
of IgA+ cells in the small intestine and by the higher produc-
tion of IL-2, IL-6, and total secretory IgA in the lumen during
the feeding period. The beneficial effects could be linked to IL-6
and IgA, which are known to be responsible for improved mucosal
homeostasis and immunological defense (Brandtzaeg et al., 1987).
It is important stress that in the above mentioned study by
Vinderola et al. (2007a), NBFs were prepared by simple centrifuga-
tion; therefore, it is not possible to claim that the observed activity
was due to milk-derived bioactive peptides. Recently, Stuknyte
et al. (2011) observed a clear reduction of the immunomodula-
tory properties of casein hydrolyzates (CHs) when the bacterial
cells of L. helveticus MIMLh5 (used for the digestion of casein)
were removed by ultrafiltration through a 3 kDa-cut off mem-
brane but not by centrifugation. Compared to whole CHs, the
cell-free ultra-filtrate did not reduce the activation of NF-κB in the
reporter system based on recombinant intestinal epithelial Caco-
2 cells, indicating that the immunomodulatory activity of strain
MIMLh5 was very likely dependent on the presence of bacterial
cells rather than on the production of casein-derived bioactive
peptides.
The same strain of L. helveticus, MIMLh5, has recently been
demonstrated to exert immunomodulatory effects on NF-κB acti-
vation at the oro-pharyngeal level. These experiments used an
in vitro model based on the hypopharyngeal FaDu cell line, both
at baseline and in presence of IL-1β, a cytokine used to mimic
a pro-inflammatory stimulus (Guglielmetti et al., 2010b). Since
NF-κB is a transcriptional factor involved in the activation of
several pro-inflammatory cytokines (Baldwin, 1996) and a ther-
apeutic target in several human (auto) inflammatory diseases
(Yamamoto and Gaynor, 2001), the cytokine profile triggered by
L. helveticus MIMLh5 on FaDu cells was analyzed. Strain MIMLh5
induced a different profile depending on the absence or presence of
IL-1β. At baseline, MIMLh5 significantly reduced the levels of pro-
inflammatory cytokines TNF-α, IL-8, and IL-6. In the presence of
IL-1β, MIMLh5 increased IFN-γ, GM-CSF, and IL-6. A possible
explanation for this different behavior may lie in the activation of
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a heat-shock response, mediated by the bacterial induction of the
heat-shock protein gene hsp70 that is known to exert protective
effects on cytokine transcripts (Laroia et al., 1999). This expla-
nation is also consistent with the reduction of NF-κB activation
(Bao and Liu, 2009). The different effects of L. helveticus on IL-
6, a pleiotropic cytokine associated with both pro-inflammatory
(Papanicolaou et al., 1998) and anti-inflammatory events (Xing
et al., 1998), is particularly interesting. L. helveticus MIMLh5 also
increased the levels of GM-CSF, a factor required for myeloid den-
dritic cell (DC) survival, leading to a higher GM-CSF/G-CSF ratio.
This ratio is associated with a switch of the immune response to
a Th1 profile, which is also consistent with the observed induc-
tion of TNF-α and IL-2 in bone marrow-derived DCs stimulated
with MIMLh5 (Guglielmetti et al., 2010b). These results suggest
that MIMLh5 can potentially exert immunomodulatory effects on
pharyngeal cells and elicit systemic immune responses. Activated
DCs, together with the production of IL-2 (Granucci et al., 2003),
are necessary to prime natural killer (NK) cells to produce IFN-
γ and to induce a Th1 response. In a subsequent study, strain
MIMLh5 was tested together with the oral isolate S. salivarius ST3
(Guglielmetti et al., 2010a) on the human macrophage U937 cell
line (Taverniti et al., 2012). The combination of MIMLh5 and
ST3 elicited a balanced ratio of TNF-α and IL-10 that might be
produced by a mild activation of the immune system and may
be useful for combating infections, potentially without causing
a detrimental outcome. Moreover, the combined administration
of the two strains affected the activation of COX2, an enzyme
involved in the synthesis of prostaglandins and in inflammatory
processes (Funk, 2001). COX2, has recently been demonstrated
to have a positive impact on the host’s health because of its role
in inducing oral tolerance, resolving inflammation, and restoring
mucosal integrity (Williams et al., 1999; Morteau et al., 2000).
Another example of the immunomodulatory properties of
L. helveticus outside the gut was reported for strain HY7801,
which was demonstrated to modulate the immune response in
the vagina. The oral administration of L. helveticus HY7801 in C.
albicans-infected mice induced a reduction of NF-κB activation
in vaginal tissue, decreased the expression of IL-1β, TNF-α, IL-6,
COX2, and iNOS, and increased the expression of IL-10. Moreover,
the same anti-inflammatory activity was confirmed in peritoneal
macrophages, since L. helveticus efficiently counteracted the LPS-
induced inflammatory response in macrophages isolated from
mouse peritoneal cavities (Joo et al., 2012).
In summary, several in vitro and in vivo studies confirmed
that specific strains of L. helveticus can exert significant beneficial
immunomodulatory properties. L. helveticus can act on the intes-
tine, the vaginal mucosa, or the pharyngeal epithelium, through
application of bacterial cells, bacterial cell components, or bacte-
rially produced bioactive molecules. In conclusion, L. helveticus
has the ability to support cross-talk with host’s immune system,
potentially causing beneficial outcomes at the local and systemic
levels.
OTHER PROPOSED HEALTH-PROMOTING PROPERTIES OF L.
hELVETICUS
Several studies suggested that strains of L. helveticus can influence
several different aspect of the host’s physiology. In a study per-
formed by Matar et al. (1997), milk fermented by L. helveticus L89
and filtered through a 0.22µm microporous membrane showed an
inhibitory effect on mutagenesis induced by 4-nitroquinoline-N ′-
oxide in the Ames genotoxicity test (Maron and Ames, 1983). On
the contrary, milk fermented by the non-proteolytic variant Prt−
of the same L. helveticus strain did not have significant activity, sug-
gesting that peptides released during fermentation are responsible
for the antimutagenic effect.
Vinderola et al. (2007a) observed that the administration of the
NBF of milk fermented by L. helveticus R389 caused a transient
activation of calcineurin (a phosphatase involved in the regulation
of both Ca2+ pumps and exchangers for the maintenance of Ca2+
homeostasis; Bandyopadhyay et al., 2002) and enhanced the tran-
scription of the T cell stimulating factor IL-2. The administration
of NBF to mice also caused increased expression of the transient
receptor potential channel (TRP) V6, a specific channel for Ca2+,
which induced an increase of Ca2+ uptake. Furthermore, NBF
administration increased the number of local mast cells and goblet
cells, which take part in providing epithelium protection through
the production of mucus. In summary, administration of NBF
resulted in an improvement of the host’s nutritional status and
defense due to improved intestinal barrier functions and surveil-
lance. The effect of L. helveticus supplementation on nutritional
status has been also documented in other studies. For instance,
the administration of a multi-strain probiotic preparation con-
taining L. helveticus strain LAT 179 to broiler chickens caused an
increase in body weight and serum albumin levels, an increase in
serum levels of minerals (i.e., calcium and potassium), a decrease
in triglyceride levels and an improved antioxidant status (Cap-
carova et al., 2011). In another study, the administration of an
aproteic diet with L. helveticus Bionan (Nestlé, Brazil) in com-
bination with S. thermophilus protected the colonic mucosa of
mice by counteracting the effect of malnutrition and restoring
the number of goblet cells (Dock-Nascimento et al., 2007). Anal-
ogously, the same probiotic preparation administered to mice in
pre- and post-operative periods stimulated the immune system,
increased the production of serum IgA and increased colonic
weight (Aguilar-Nascimento et al., 2006).
Fermented milk whey containing L. helveticus also proved ben-
eficial in ameliorating induced dermatitis in a murine model. The
oral administration of milk fermented with L. helveticus strain
CM4 decreased transepidermal water loss and the size of der-
matitis area in SDS-exposed Hos:HR-1 hairless mice, improving
skin moisture content. On the contrary, no significant effects
were exerted by artificially acidified milk whey (Baba et al.,
2010). In vitro experiments on human epidermal keratinocytes
supplemented with the same fermented milk whey preparation
identified an increase in profilaggrin mRNA, a precursor of filag-
grin that is involved in epidermal hydration and flexibility and
is a marker of epidermal terminal differentiation (Baba et al.,
2006).
Oral administration of L. helveticus R0052 and B. longum
R0175 (formulation PF; Probio’Stick, Institute Rosell-Lallemand,
Montreal, QC, Canada) to mice after induced myocardial infarc-
tion (MI) was effective in attenuating the resulting symptoms
of depression (Arseneault-Bréard et al., 2012). Feeding with PF
improved intestinal barrier integrity and depression symptoms,
measured by various behavioral and social interaction tests per-
formed on mice. Moreover, PF administration induced a reduction
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in circulating IL-1β levels (Arseneault-Bréard et al., 2012). These
data suggest that L. helveticus species can potentially influence the
gut-brain axis and thus affect the central nervous system (Neufeld
and Foster, 2009), as also proposed by studies of the connec-
tion between stress and gastrointestinal disorders (Forsythe et al.,
2010). The same probiotic formulation containing L. helveticus
R0052 and B. longum R0175 (PF) attenuated apoptosis in the lim-
bic region (involved in the pathophysiology of depression) that can
occur after MI, measured by a reduction in caspase-3 activation
(Girard et al., 2009). This effect was hypothesized to be due to a
reduction of pro-inflammatory cytokines, which can be involved
in apoptosis (Wann et al., 2006). Administration of PF was also
effective in attenuating anxiety-like behavior in rats and anxiety
symptoms in normal volunteers who took PF daily for 30 days.
Volunteers scored lower on the Hopkins Symptoms Checklist
(HSCL)-90, a 90-item self-reported questionnaire that evaluates
several behavioral and emotional parameters, such as somatiza-
tion, depression, and anger-hostility. It has been hypothesized that
probiotics may exert their anxiolytic effects by competing with
pathogens, since gastrointestinal infections seem to affect the brain
area that connects viscerosensory information and mood via the
vagus nerve, leading to changes in neurotransmitter levels and
functions.
Beneficial effects of L. helveticus-fermented products were also
reported on sleep quality. A preparation obtained through the fer-
mentation of milk with L. helveticus CM4 administered for 3 weeks
to healthy elderly people resulted in a decrease in the number
of wake episodes and a global improvement of sleep quality, as
revealed by a questionnaire and confirmed by actigraphy analysis.
The effect was suggested to be due to the presence of a tripeptide
produced by L. helveticus during milk fermentation that inhibits
angiotensin-I-converting enzyme (ACE) activity (consistent with
the fact that certain antidepressant drugs act as inhibitors of ACE;
Zubenko and Nixon, 1984) or, more likely, to the production of
bioactive peptides that act on GABAergic or serotonergic neurons
(Yamamura et al., 2009).
ACE INHIBITORY ACTIVITY
Angiotensin-I-converting enzyme (ACE; peptidyl-dipeptide
hydrolase, EC 3.4.15.1) is a dipeptidyl carboxypeptidase located in
different tissues of the human body. ACE is responsible for increas-
ing blood pressure by converting angiotensin-I to the potent
vasoconstrictor angiotensin-II and by degrading the vasodilator
bradykinin (Campbell, 1987). Several studies demonstrated that
fermentation and/or digestion processes liberate small peptides
from several food proteins that inhibit the ACE activity (Abubakar
et al., 1998; Dziuba et al., 1999; Fitzgerald and Meisel, 2000; Gob-
betti et al., 2000). Interest in ACE inhibitory peptides was amplified
by the experimental observation that they may exert an antihyper-
tensive effect after oral administration (Vermeirssen et al., 2004).
A large number of studies proved that among LAB, L. helveticus
has the highest capacity to form ACE inhibitory peptides from
food proteins as a consequence of the marked activity of its cell
envelope-associated proteinases (CEPs; Yamamoto et al., 1993).
The first observations of the ability of L. helveticus to generate
ACE inhibitory peptides date back to the nineties, when Yamamoto
et al. (1994a) showed that the peptides liberated from casein by the
CEP activity of L. helveticus CP790 were able to suppress ACEs. The
same authors found that the ACE inhibitory activity was higher
in the whey fractions of milk fermented with L. helveticus than
in milk fermented with other LAB, including L. delbrueckii, L.
casei, Streptococcus thermophilus, Lactococcus lactis and, notably, L.
acidophilus (Yamamoto et al., 1994b). Accordingly, they observed
that fermented milk, upon oral administration, significantly low-
ered blood pressure in spontaneously hypertensive rats only if the
milk was prepared with L. helveticus strains and not with other
LAB (Yamamoto et al., 1994b).
The ACE inhibitory activity of milk fermented with L. helveti-
cus has been linked to several different peptides, mainly originating
from the digestion of the αs1, β, and κ fractions of casein (Takano,
1998). Specifically, the following amino acidic sequences have been
associated with ACE inhibitory peptides: Ala-Tyr-Phe-Tyr-Pro-
Glu, Ser-Lys-Val-Leu-Pro-Val-Pro-Gln (Yamamoto et al., 1994a),
Val-Pro-Pro and Ile-Pro-Pro (Nakamura et al., 1995), Lys-Val-Leu-
Pro-Val-Pro-Gln (Maeno et al., 1996), and Tyr-Pro (Yamamoto
et al., 1999).
More recently, it was demonstrated that the L. helveticus strain
LMG11474 can produce considerable amounts of ACE inhibitory
peptides by the fermentation of pea proteins (Vermeirssen et al.,
2003). However, the ability of L. helveticus to generate ACE
inhibitory peptides from food proteins other than casein has only
been marginally investigated.
Many in vivo trials assessed the suitability of LhFM as an addi-
tional or alternative treatment for hypertension. The ability of
LhFM to reduce blood pressure has been demonstrated in sev-
eral studies employing a spontaneously hypertensive rat model
(Yamamoto et al., 1994b; Takano, 1998; Sipola et al., 2001; Jakala
et al., 2009). Moreover, promising results supporting the ability of
LhFM to reduce blood pressure have also been obtained in human
clinical studies. A meta-analysis of 12 randomized controlled tri-
als published in 2008 provided evidence that fermented milk has
hypotensive effects in both prehypertensive and hypertensive sub-
jects. Interestingly, nine out of the 12 randomized controlled trials
included in the meta-analysis were based on milk fermented with
L. helveticus (Xu et al., 2008).
More recent double-blind, randomized, placebo-controlled,
parallel group studies showed that the long-term (3 months)
intake of milk fermented by L. helveticus (strain LBK-16 H) con-
taining Ile-Pro-Pro and Val-Pro-Pro tripeptides reduced systolic
and diastolic blood pressure in 24-h readings. The differences
between the treatment group and the placebo group were not sta-
tistically significant, but the authors concluded that the observed
effect may have clinical significance (Jauhiainen et al., 2010, 2012).
In addition, Usinger et al. (2010) recently reported that LhFM
(strain Cardi04) did not inhibit ACE in humans. Furthermore,
they reported that 24-h ambulatory blood pressure measurements
failed to reveal significant antihypertensive effects during an 8-
week intervention study based on the consumption of 150 or
300 ml of LhFM, even though the group receiving 300 ml of LhFM
had reduced blood pressure across the 8-week period in several
readings (Usinger et al., 2010). It has been proposed that diver-
gent or statistically insignificant results in human studies can
be explained by the marked subject-to-subject variability in the
effects of lactotripeptides (Pripp, 2008; Xu et al., 2008; Cicero et al.,
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Table 1 | Reported health-promoting activities displayed by bacterial strains belonging to Lactobacillus helveticus species.
L. helveticus
Strain
Health-promoting agent Activity Type of study Reference
R389 Bacterial cells Protective action against Salmonella enteritidis
serovar Typhimurium infection
In vivo, mouse Vinderola et al. (2007b)
R0052 Viable and heat-inactivated
bacterial cells
Reduction of Campylobacter jejuni invasion in
human colon cancer epithelial T84 cells
In vitro Ternhag et al. (2008)
Bacterial cells in association
with Lactobacillus rhamnosus
Amelioration of mucosal barrier functions and
colonic epithelial cells hyperplasia in mice infected
with Citrobacter rodentium
In vivo Gareau et al. (2010)
Bacterial cells Blocking of innate immunity pathogen-subversion
by interfering with E. coli O157:H7-induced
inhibition of STAT-1 tyrosine phosphorylation in 407,
Caco-2 and HEp cells
In vitro Jandu et al. (2009)
Isolated S-layer protein Inhibition of E. coli O157:H7 adhesion on intestinal
epithelial HEp-82 cells and pathogen-induced drop
in trans-epithelial resistance on T84 cell line
In vitro Johnson-Henry et al. (2007)
M92 Isolated S-layer protein Mediation of bacterium auto-aggregation and
co-aggregation with Salmonella Typhimurium FP1
In vivo, mouse Beganovic et al. (2011)
MIMLh5 Bacterial cells Adhesion to human hypopharyngeal epithelial FaDu
cells and HaCat keratinocytes; competitive
exclusion against Streptococcus pyogenes
In vitro Guglielmetti et al. (2010b)
KS300 Bacterial cells Inhibition of growth and viability of
vaginosis-associated bacteria and pathogen
adhesion on human cervical Hela and Caco-2/TC7
enetrocyte-like cell lines
In vitro, human Atassi et al. (2006)
HY7801 Bacterial cells Inhibition of Candida albicans-induced vaginitis and
reduction of myeloperoxidase activity in vaginal
tissue
In vivo, mouse Joo et al. (2012)
M92 Bacterial cells alone and in
association with prebiotic
fibers
Increase of total lactic acid bacteria (LAB) fecal
counts; reduction of total enterobacteria and
sulfur-reducing clostridia levels in fecal samples
In vivo, mouse Frece et al. (2009)
Bacterial cells Decrease of total enterobacterial and Salmonella
spp. fecal counts
In vivo, mouse Beganovic et al. (2011)
416 Association with
Enterococcus faecium CRL
183 in aqueous soy extract
Reduction of the Enterobacteriaceae population,
increase in Enterococcus spp., Lactobacillus spp.
and Bifidobacterium spp. fecal counts.
Amelioration of lipid profile. Reduction of
atherosclerotic lesion area in aortic segments
In vivo, rabbit Cavallini et al. (2011)
Bc-10 Viable and heat-inactivated
bacterial cells; intracellular
cell-free extract
Inhibition of leukotriene B4 production on J774 cell
line
In vitro, mouse Kimoto-Nira et al. (2009)
Bar13 Bacterial cells Increase in butyrate and decrease in pyridine levels
in fecal samples
In vitro, humans Vitali et al. (2012)
KS300 Bacterial cells Increase in Lactobacillaceae and Moraxellaceae
vaginal levels and decrease in Pastereullaceae
population
In vitro, human Atassi et al. (2006)
(Continued)
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Table 1 | Continued
L. helveticus
Strain
Health-promoting agent Activity Type of study Reference
R0052 Bacterial cells in association with
Bifidobacterium longum and
Streptococcus thermophylus in
soy and milk fermented
preparations
Decrease in TNF-α-induced expression of IL-8 in
human epithelial HT29 and T84 cells
In vitro Wagar et al. (2009)
LH-2 Whole fermented milk and
cell-free supernatant
Stimulation of IL-6 secretion in macrophages In vitro Ng and Griffiths (2002)
5089 Ultra-filtered fermented
β-casein-permeate
Proliferation of human peripheral-blood
lymphocytes
In vitro Laffineur et al. (1996)
R389 Whole fermented milk and
non-bacterial fraction
Increase in immunoglobulin (Ig)-A producing cells
in the lamina propria and in luminal content of total
S-IgA and specific anti-Salmonella IgA
In vivo, mouse Vinderola et al. (2007c)
Peptidic fraction of fermented
milk
Increase of IgA producing B-lymphocytes, total
intestinal IgA secretion and total serum IgA in mice
infected with E. coli O157:H7
In vivo Leblanc et al. (2004)
M92 Milk supplemented with viable
bacterial cells alone and in
association with prebiotics
Augmentation of fecal secretory IgA levels and
total serum IgA in mice
In vivo Frece et al. (2009)
R389 Peptidic fraction of fermented
milk
Induction of a Th2 responses (high IL-4 serum
levels)
In vivo, mice Leblanc et al. (2004)
Different peptide size fractions
from fermented milk
Increase of IgA+B cells at mucosal gut level;
amelioration of induced-tumor in mice
In vivo LeBlanc et al. (2002)
Fermented milk Induction of IgA-secreting cells in small intestine
and in bronchus in mice
In vivo Matar et al. (2001)
Milk fermented with wild-type
and a non-proteolytic variant
Regression of a subcutaneous
implanted-fibrosarcoma in mice; activation of the
phagocytic activity in mouse peritoneal
macrophages
Ex vivo, in vivo Matar et al. (2001)
Whole fermented kefir and
cell-free kefir
Breast cancer growth delay In vivo, mouse de Moreno de LeBlanc et al.
(2006)
R389; L89 Fermented milk Breast cancer regression In vivo, mouse de Moreno de LeBlanc et al.
(2005)
R389 Fermented milk Increase of IL-10 and decrease of IL-6 levels in the
serum and in mammary glands
In vivo, mouse de Moreno de LeBlanc et al.
(2005)
R389 Non-bacterial fraction of
fermented milk
Increase of IgA+ cells in small intestine, production
of IL-2, IL-6, and total secretory IgA in the lumen
In vivo, mouse Vinderola et al. (2007a)
MIMLh5 Casein hydrolyzates Reduction of NF-κB activation in human epithelial
Caco-2 cells
In vitro Stuknyte et al. (2011)
Bacterial cells Reduction of NF-κB activation and induction of
distinct cytokine profile on human FaDu cells in
different physiological conditions; stimulation of
TNF-α and IL-2 production in mouse bone
marrow-derived dendritic cells
In vitro, ex vivo Guglielmetti et al. (2010b)
Bacterial cells in association with
Streptococcus salivarius ST3
Stimulation of innate immune responses in human
macrophages U937 cells
In vitro Taverniti et al. (2012)
(Continued)
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Table 1 | Continued
L. helveticus
Strain
Health-promoting agent Activity Type of study Reference
HY7801 Bacterial cells Reduction of NF-κB and pro-inflammatory
cytokines expression in Candida albicans-infected
mice; anti-inflammatory action on LPS-stimulated
peritoneal macrophages
Ex vivo, in vivo Joo et al. (2012)
L89 Ultra-filtered fermented milk Inhibition of induced-mutagenesis (Ames test) In vitro Matar et al. (1997)
R389 Non-bacterial fraction of
fermented milk
Improvement of Ca2+ uptake through activation of
calcineurin and TRPV6 channel; increase of mast
cells and goblet cells number
In vivo, mice Vinderola et al. (2007a)
LAT179 Bacterial cells in a multi-strain
probiotic preparation
Increase of body weight, albumin serum level and
amelioration of mineral parameters, antioxidant
status and lipid profile in broiler chickens
In vivo Capcarova et al. (2011)
Bionan Bacterial cells in association
with S. thermophylus
Protection of colonic mucosa in mice fed with
aproteic diet
In vivo Dock-Nascimento et al. (2007)
Bacterial cells in association
with S. thermophylus
Increase of colonic weight and serum IgA levels in
pre and post-operative period
In vivo, mice Aguilar-Nascimento et al.
(2006)
CM4 Fermented whey milk Amelioration of induced dermatitis in mice In vivo Baba et al. (2010)
Fermented whey milk Improvement of epidermal differentiation in human
epidermal keratinocytes
In vitro Baba et al. (2006)
R0052 Bacterial cells in a probiotic
preparation with B. longum
Attenuation of post-myocardial infarction
depression symptoms in mice
In vivo Arseneault-Bréard et al. (2012)
Bacterial cells in a probiotic
preparation with B. longum
Reduction of apoptosis in limbic region in rats In vivo Girard et al. (2009)
Bacterial cells in a probiotic
preparation with B. longum
Anxiolytic effect in rats; attenuation of anxiety
symptoms in human volunteers
In vivo Messaoudi et al. (2011)
CM4 Fermented milk Amelioration of sleep quality in elderly people In vivo, humans Yamamura et al. (2009)
CP790 Casein hydrolyzates Angiotensin-I-converting enzyme inhibitory (ACEI)
activity, decrease of blood pressure in
spontaneously hypertensive rats
In vivo Yamamoto et al. (1994a)
LMG11474 Fermented-pea proteins Release of ACE inhibitory peptides (ACE inhibition
assay)
In vitro Vermeirssen et al. (2003)
LBK-16 H Fermented milk Reduction of systolic and diastolic blood pressure In vivo, humans Jauhiainen et al. (2010, 2012)
MVLH1; MVLH2 Bacterial cells Inactivation of heterocyclic aromatic amines In vitro Stidl et al. (2008)
B1 Bacterial cells alone and in
association with S.
thermophylus in milk
Decrease of antigenicity of caw milk α-lactalbumin
and β-lactoglobulin
In vitro Bu et al. (2010)
MIMLh5; SLh02 Cinnamoyl esterase activity Reduction of allergenic caffeic acid esters content
in propolis
In vitro Gardana et al. (2012)
MIMLh5 Cinnamoyl esterase activity Improvement of antioxidant potential of apple pulp
through increase of hydroxycinnamic acids
bioavailability
In vitro Guglielmetti et al. (2008)
R0052 γ-glucosidase activity Increase of isoflavones bioavailability and
antioxidant activity
In vitro Champagne et al. (2010)
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2011), which may mask the effects of clinically significant mean
blood pressure reductions (Jauhiainen et al., 2012).
In conclusion, results from human interventional trials indicate
that LhFM produces at least mild antihypertensive effects.
INDIRECT HEALTH-PROMOTING EFFECTS OF L. hELVETICUS
In addition to the production of ACE inhibitory peptides from
food proteins, L. helveticus can indirectly benefit the host’s health
by reducing allergens or toxic compounds and increasing the
bioavailability of specific nutrients in foodstuffs.
Stidl et al. tested the capacity of eight LAB species (12
strains per species) to inactivate five heterocyclic aromatic
amines (HACs), including the molecules 2-amino-1-methyl-
6-phenyl-imidazo[4,5-b]pyridine and 2-amino-9H-pyrido[2,3-
b]indole, which are the most abundant mutagens in fried red meat.
The inactivation of the amines with LAB resulted in a decrease of
their mutagenic potential and correlated with the HCA-binding
capacities of the single strains. Notably, this study showed that the
overall inactivation of the different HCAs by L. helveticus (calcu-
lated to be about 83%) was the highest among the tested bacteria,
which also included L. delbrueckii susp. bulgaricus (59%) and L.
acidophilus (20%; Stidl et al., 2008).
In a subsequent study, L. helveticus fermentation was shown
to significantly decrease the antigenicity of whey proteins in skim
milk. Bu et al. (2010), using indirect competitive ELISA, observed
that strain L. helveticus B1, alone or in combination with S.
thermophilus, was the most effective in reducing the antigenic-
ity of α-lactalbumin and β-lactoglobulin, the major allergens in
cow’s milk.
More recently, L. helveticus was successfully employed in a
biotransformation aimed to remove allergenic molecules from
propolis (bee glue). Propolis is a resinous, sticky, dark-colored
material produced by honeybees (Apis mellifera), which is exten-
sively used as a natural ingredient in food formulations and sup-
plements. A study by Gardana et al. (2012) demonstrated that
the cinnamoyl esterase activity of L. helveticus strains MIMLh5
and SLh02 can significantly degrade the major allergens in
propolis, including esters of caffeic acid such as methyl-butenyl-
caffeates.
In a previous study, the strong cinnamoyl esterase activity of
L. helveticus strain MIMLh5 was employed to ferment Renetta
cultivar apple pulp with the aim of converting the chlorogenic
acid into free caffeic acid. Caffeic acid and chlorogenic acid are
potent antioxidant molecules that have been associated with sev-
eral health-promoting effects in vivo (Suzuki et al., 2002; Takeda
et al., 2002; Touaibia et al., 2011; Weng and Yen, 2012). Nonethe-
less, the biological properties of these hydroxycinnamic acids
depend on their absorption by the gastrointestinal tract. Whereas
the majority of chlorogenic acid reaches the large intestine and
is quickly degraded by the microbiota, free caffeic acid is well
absorbed in the stomach and small intestine, resulting in a higher
plasma concentration of this molecule and its metabolites than
chlorogenic acid. Therefore, the fermentation of Renetta apple
pulp by L. helveticus strain MIMLh5 could significantly increase
the bioavailability of hydroxycinnamic acids by preserving the
overall antioxidant power of apple pulp (Guglielmetti et al.,
2008).
The capacity of L. helveticus to increase the bioavailability of
specific nutrients was also demonstrated with soy isoflavones (SIs).
SIs are polyphenolic compounds with estrogen-like effects, which
have been associated with health benefits as a consequence of
their antioxidant (Ruiz-Larrea et al., 1997) and anti-inflammatory
activities (Huang et al., 2005). The main isoflavones of soy
(daidzin, genistin, glycitin) are naturally present as β-glucosides,
which are not readily bioavailable in humans since they are very
poorly absorbed through the intestinal tract (Donkor and Shah,
2008). The γ-glucosidase activity of Lactobacillus helveticus R0052
during soy fermentation can convert isoflavone glucosides into
aglycone forms, improving the bioavailability of these molecules
(Champagne et al., 2010).
In conclusion, the few examples that we mentioned demon-
strate that L. helveticus strains possess enzymes, such as CEPs,
cinnamoyl esterase, or β-glucosidase, which can contribute to the
improvement of food quality and safety.
CONCLUSION
L. helveticus is a “Generally Recognized as Safe” (GRAS) microor-
ganism, which was given the “Qualified Presumption of Safety”
(QPS) status by the European Food Safety Authority (EFSA)
(2007). The QPS is the EFSA’s safety evaluation label based on “the
body of knowledge” or “familiarity” of a microorganism. There-
fore, L. helveticus deserves QPS status, since it has a long history
of apparent safe use in the food chain, is sensitive to most antibi-
otics and lacks acquired antibiotic resistance (Rossetti et al., 2009;
Guglielmetti et al., 2010b).
In addition to the mandatory requirements for safety (Food
and Agriculture Organization/World Health Organization, 2002),
a microbial strain has to demonstrably benefit the host’s health
in order to be considered a probiotic, according to the currently
accepted definition. In this manuscript, we reviewed the litera-
ture indicating that different L. helveticus strains can positively
influence the host’s physiology and prevent or treat pathologic
conditions. Several mechanisms of action have been proposed by
in vitro studies, such as the direct inhibition of pathogens, the
stimulation of DCs and macrophages, or the modulation of host
gene expression. Furthermore, in vivo clinical and interventional
trials have substantiated the probiotic efficacy of L. helveticus.
In conclusion, this review demonstrated that strains belonging
to the L. helveticus species can display probiotic properties that
are not dissimilar from those displayed by microorganisms con-
ventionally considered to be probiotics, such as L. acidophilus, L.
rhamnosus, and Bifidobacterium animalis subsp. lactis. Addition-
ally, properties such as the production of ACE inhibitory peptides
or cinnamoyl esterase activity are unique to L. helveticus strains
and provide support for use of this bacterium over other probiotic
species. L. helveticus can adapt to industrial fermentation condi-
tions more easily than most intestinal probiotic lactobacilli and
bifidobacteria, due to its ability to survive various environmental
stresses such as high temperatures or low pH, osmotic pressure,
and oxygen, which facilitates its incorporation into new probiotic
formulas.
Considering the existing scientific knowledge on the health-
promoting properties of L. helveticus (Table 1), this bacterial
species can be properly considered to be probiotic.
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